Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction

Sponsor
Xiros Ltd (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05264389
Collaborator
(none)
55
1
77
0.7

Study Details

Study Description

Brief Summary

This is a Post Market Clinical Follow Up Study in Orthopaedics, it will verify the long-term safety and performance of the device in the intended patient population, when indicated for the reconstruction of a ligament in the kneecap, the Medial Patellafemoral ligament (MPFL). The Medical Device in this study Poly-Tape is a Class IIb CE- Marked device manufactured by Xiros Ltd. Poly-tapes are a single-use device, they are indicated for patients repair of soft tissue and/or reconstruction of ligaments, tendons, and other soft tissues. The device can be fixed to the bone using several different methods including screws.

This study is a prospective, multicentre, consecutively recruited non- randomised study. The total length of the study is expected to be 7 years. This includes a recruitment period of approximately 24 months and a 5-year follow- up. A total of 55 subjects will be enrolled into the study with follow up at 6 months, 1 year, 2 years and 5 years in clinic and by questionnaires. All subjects treated with the Polytape for MPFL reconstruction, will be consecutively recruited into the study.

Condition or Disease Intervention/Treatment Phase
  • Device: Poly-Tape

Study Design

Study Type:
Observational
Anticipated Enrollment :
55 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction
Actual Study Start Date :
Dec 17, 2021
Anticipated Primary Completion Date :
May 17, 2024
Anticipated Study Completion Date :
May 17, 2028

Arms and Interventions

Arm Intervention/Treatment
Poly-Tape Device

Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction

Device: Poly-Tape
Poly-Tape Device for Medial Patellofemoral Ligament (MPFL) Reconstruction

Outcome Measures

Primary Outcome Measures

  1. Kujala Score [1 year]

    The primary performance objective is to determine the effect of MPFL reconstruction on symptoms and functional limitations 1 year after surgery, measured using the Kujala .Total score. Total scores range from 0 to 100 with high scores indicating good

  2. Redislocation/subluxation events [1 year]

    The primary safety objective is to assess redislocation/subluxation events at 1 year after surgery

Secondary Outcome Measures

  1. Full range of motion (ROM) [5 years]

    Secondary performance objectives are to determine the effect of MPFL reconstruction on the following during the performance lifetime of the device: Full range of motion (ROM)

  2. Norwich Patellar Instability (NPI) score [5 years]

    Change from baseline Norwich Patellar Instability (NPI) score at each visit up to 1 year. The score is made up of 0 to 250. Out of the total score-able answers, where "don't do" answered questions are deducted, the total score is then converted as a percentage based on the number of scored responses provided. A higher percentage indicate higher severity of patellar instability

  3. Patient-reported quality of life (Short form 36) [5 years]

    Secondary performance objectives are to determine the effect of MPFL reconstruction on the following during the performance lifetime of the device: Patient-reported quality of life 0-100 a higher sore indicates a higher health state

  4. Patient-reported activity levels [5 years]

    Secondary performance objectives are to determine the effect of MPFL reconstruction on the following during the performance lifetime of the device: Patient-reported activity levels 0-10 , 10 is a high level of activity

  5. Patient satisfaction with Surgery [5 years]

    Secondary performance objectives are to determine the effect of MPFL reconstruction on the following during the performance lifetime of the device: Patient satisfaction with Surgery. Yes or No

  6. Adverse events, including re-dislocation/subluxation [5 years]

    Secondary safety objectives include: Adverse events, including

Eligibility Criteria

Criteria

Ages Eligible for Study:
13 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patient must be 13 years old or above. Patients who require MPFL reconstruction. Patients willing to participate in the study and have been informed of the nature of the study, agree to its follow-up and have provided written informed consent as approved by the Research Ethics Committee (REC).

Exclusion Criteria:

These devices should not be used in procedures which bridge, disturb, or disrupt the growth plate in immature patients since they will not elongate as the patient grows.

Patients known to be hypersensitive to titanium alloy or polyester. Appropriate tests should be carried out on patients with suspected material sensitivity prior to implantation.

Patients with any infections or structural or pathological condition of the bone or soft tissue that would be expected to impair healing or secure fixation. Bone quality should be assessed prior to surgery.

Patients who are unable or unwilling to restrict activities to prescribed levels or to follow the rehabilitation instructions during the healing period.

Patients for whom the implantation is intended to be non-permanent, since they integrate well with the patient's tissue.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hampshire Hospitals NHS Foundation Trust Winchester United Kingdom SO22 5DG

Sponsors and Collaborators

  • Xiros Ltd

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xiros Ltd
ClinicalTrials.gov Identifier:
NCT05264389
Other Study ID Numbers:
  • CRE 022
First Posted:
Mar 3, 2022
Last Update Posted:
Apr 4, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2022